Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis.
Bich Doan Nguyen-SträuliJoanna BaumPhilipp Meyer-WilmesAnne KreklauChristina BuschmannNabila El OuardiChristina FotopoulouMichael HummelRadoslav ChekerovElena BraicuJalid SehouliKlaus PietznerPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)
Adequate structure for BRCA/HR deficiency testing, and systematic education programs are needed to prevent delay in counseling and undertreatment of women with epithelial ovarian cancer. In Germany, a combination of olaparib and bevacizumab seems to be the preferred treatment in the first-line setting.
Keyphrases
- quality improvement
- palliative care
- healthcare
- endometrial cancer
- primary care
- dna damage
- public health
- south africa
- replacement therapy
- cross sectional
- dna repair
- smoking cessation
- single molecule
- hiv testing
- middle aged
- oxidative stress
- metastatic colorectal cancer
- human immunodeficiency virus
- hiv infected
- men who have sex with men
- antiretroviral therapy